anti-latent TGFb1 monoclonal antibody RO7496353
Term · Oncology and biomedicine · MLC-T-ONC-010857
A monoclonal antibody directed against latent human transforming growth factor (TGF)-beta 1 (TGFb1; TGF-b1), with potential antineoplastic activity. Upon administration, anti-latent TGFb1 monoclonal antibody RO7496353 targets, binds to, and inhibits the activation of latent TGFb1 complexes, thereby preventing TGFb1-mediated signaling. This abrogates TGFb1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFb1-dependent proliferation of cancer cells. The TGF-beta signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME. TGFb1 is the predominant isoform in many tumors.
| Identifier | MLC-T-ONC-010857 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-latent TGF-beta1 monoclonal antibody RO7496353; anti-latent TGF-beta 1 monoclonal antibody RO7496353; anti-latent TGF-beta1 monoclonal antibody SOF10; anti-latent TGF-beta1 monoclonal antibody RG6440 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010857",
"term": "anti-latent TGFb1 monoclonal antibody RO7496353",
"field": "Oncology and biomedicine",
"definition": "A monoclonal antibody directed against latent human transforming growth factor (TGF)-beta 1 (TGFb1; TGF-b1), with potential antineoplastic activity. Upon administration, anti-latent TGFb1 monoclonal antibody RO7496353 targets, binds to, and inhibits the activation of latent TGFb1 complexes, thereby preventing TGFb1-mediated signaling. This abrogates TGFb1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFb1-dependent proliferation of cancer cells. The TGF-beta signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME. TGFb1 is the predominant isoform in many tumors.",
"synonyms": [
"anti-latent TGF-beta1 monoclonal antibody RO7496353",
"anti-latent TGF-beta 1 monoclonal antibody RO7496353",
"anti-latent TGF-beta1 monoclonal antibody SOF10",
"anti-latent TGF-beta1 monoclonal antibody RG6440"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-latent-tgfb1-monoclonal-antibody-ro7496353/"
}
Record 1,974 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.